Kashiv BioSciences and MS Pharma have entered into a license and supply agreement for ADL-018, Kashiv BioSciences’ biosimilar candidate to Genentech and Novartis AG’s Xolair (omalizumab) in the Middle ...
PISCATAWAY, N.J., August 05, 2025--(BUSINESS WIRE)--Kashiv BioSciences, LLC and MS Pharma today announced that the companies have entered into a license and supply agreement for ADL-018, Kashiv ...
RIYADH, Saudi Arabia, Aug. 27, 2025 /PRNewswire/ -- MS Pharma has officially inaugurated the first biologics' manufacturing facility in the Middle East, strategically located in Saudi Arabia. The ...
MS Pharma becomes Partner for the Commercialization of FYB201, Formycon's Biosimilar Candidate to Lucentis(R)1 (ranibizumab), in the MENA Region 14.12.2021 / 08:00 The issuer is solely responsible for ...
As momentum for Biogen’s newer drugs for neurological disorders builds at a slow and steady pace, it appears that the company ...
Those who prescribe larger amounts of MS drugs were more likely to have received payments, and those who got payments were more likely to prescribe the company’s drugs, especially if the payments were ...
Kashiv BioSciences, LLC and MS Pharma today announced that the companies have entered into a license and supply agreement for ADL-018, Kashiv BioSciences’ biosimilar candidate to XOLAIR® (bOmalizumab) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback